Hyundai Pharmaceutical said on Friday that it signed a new drug development agreement with C-NOPS Design, a new drug-candidate material design company based on computer-aided design and drawing (CADD).

C-NOPS Design is a molecular design contract research organization (CRO) based on “Medichem Plus Sillico,” a software program. This molecular design technology is capable of designing and synthesizing new materials immediately rather than searching for library materials and considering the patentability and synthesis potential of materials. The company's goal is to quickly and efficiently develop candidate materials by securing and optimizing the structure of effective materials with minimal material synthesis.

Through this agreement, Hyundai Pharmaceutical plans to use C-NOPS Design's molecular design technology to discover new structures to derive new drug candidates.

Accordingly, Hyundai Pharmaceutical expects the efficient development of candidate materials to shorten the development period of new drugs and reduce the cost of developing them.

"With this agreement, we expect to create excellent synergy by discovering new candidate materials utilizing C-NOPS Design CADD strengths together with the strengths of Hyundai Pharmaceutical’s chemistry researchers.” said an official from Hyundai Pharmaceutical.

An official from C-NOPS Design added that they wish to create a successful case of efficient and practical new drug development based on this collaboration with Hyundai Pharmaceutical.